Replies to post #118576 on Biotech Values

[Regulardoc]

Or perhaps missing the cash receivable from NVS after the fourth quarter 2010 numbers reported.

On a side note, just started a patient on enoxaparin 100mg prefilled syringe this morning for DVT. Was a Sandoz label, but a bit disppointed that the package did not cantain a glossy instructional sheet for the patient. Would cost all of $.25 and would be nice for patients.

[DewDiligence]

MNTA’s effective cash balance at 12/31/10 was $202.9M. This comes from $100.7M of cash, $41.1M of marketable securities classified as current, $11.0M of marketable securities classified as non-current, and $54.5M of accounts receivable, less $4.4M of accounts payable.

[10nisman]

Looks like he is $45M low on the cash - perhaps missing the offering.

What are you talking about? MNTA likely had $190-200M in cash at March 31, not including Q1 2011 A/R of ~$70-75M.